G49N Stock Overview
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
GenSight Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.19 |
| 52 Week High | €0.44 |
| 52 Week Low | €0.16 |
| Beta | 1.97 |
| 1 Month Change | -6.02% |
| 3 Month Change | -27.92% |
| 1 Year Change | -47.06% |
| 3 Year Change | -90.37% |
| 5 Year Change | -93.56% |
| Change since IPO | -97.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| G49N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 0.2% | 0.9% |
| 1Y | -47.1% | -11.8% | 13.2% |
Return vs Industry: G49N underperformed the German Biotechs industry which returned -11.8% over the past year.
Return vs Market: G49N underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| G49N volatility | |
|---|---|
| G49N Average Weekly Movement | 16.7% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: G49N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G49N's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 16 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
| G49N fundamental statistics | |
|---|---|
| Market cap | €28.49m |
| Earnings (TTM) | -€14.00m |
| Revenue (TTM) | €2.63m |
10.9x
P/S Ratio-2.0x
P/E RatioIs G49N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G49N income statement (TTM) | |
|---|---|
| Revenue | €2.63m |
| Cost of Revenue | €0 |
| Gross Profit | €2.63m |
| Other Expenses | €16.63m |
| Earnings | -€14.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 19, 2025
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -533.37% |
| Debt/Equity Ratio | -66.9% |
How did G49N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 09:43 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GenSight Biologics S.A. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ingrid Gafanhão | Bryan Garnier & Co |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |